Skip to main content

Enzymatica announces launch plan for a proprietary mouthwash for gingivitis

Press Release   •   Feb 10, 2014 13:02 GMT

The biotechnology company Enzymatica has drawn up a launch plan for an innovative mouthwash based on the company's enzyme technology. PeriZyme® Mouthwash is a second generation product for the treatment of gum inflammation (gingivitis) and is a further development of the company's PeriZyme gum. Enzymatica plans to launch PeriZyme Mouthwash on the Swedish market during the second half of 2014.

"The development of an improved product to treat gingivitis has been in progress for some time, and we are very pleased to unveil our launch plan for the product. We expect that PeriZyme will complete the registration process with the Swedish MPA very shortly. Our strategic initiative to build an attractive product portfolio, based on our own research and development, is now producing results", said Michael Edelborg Christensen, CEO of Enzymatica.

The Swedish market for mouthwash products is estimated at just over SEK 300 million[1], with pharmacies accounting for about two-thirds of this figure and grocery stores for the remaining third. Enzymatica’s focus is on the pharmacy and dental markets.

The product will be registered as a medical device, Class I with the Swedish MPA, which gives access to the entire European market. The launch outside Sweden will be implemented gradually, within our own expanding organisation and outside through contracts with distributors.

Enzymatica’s product portfolio also includes ColdZyme® Mouth spray to combat the common cold, which was successfully introduced in Sweden during the second half of 2013.

For more information on Enzymatica, please contact:
Michael Edelborg Christensen, CEO Enzymatica AB (publ), +46 (0)768-14 41 66,

[1] Nielsen ScanTrack, 2013 

About Enzymatica AB (publ)
Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical device products based on a patented enzyme technology. Enzymatica has several projects in the pipeline for diseases of the skin, throat and mucous membranes. Enzymatica has two registered medical device products, PeriZyme® Chewing Gum CE, against oral cavity diseases and ColdZyme® Mouth Spray CE against the common cold, the latter recently launched throughout the country.

About Enzymatica online
Enzymatica’s press room »
Enzymatica’s website »
Enzymatica on LinkedIn »
Enzymatica on twitter »
For Investors »
For Investors »
ColdZyme website »
ColdZyme on facebook »

Comments (0)

Add comment